Welcome to our dedicated page for Zymeworks news (Ticker: ZYME), a resource for investors and traders seeking the latest updates and insights on Zymeworks stock.
Zymeworks Inc. (Nasdaq: ZYME) generates frequent news flow as a biotechnology and clinical-stage biopharmaceutical company managing licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics. Company announcements highlight its focus on difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, and its integrated model that combines internal R&D with an asset and royalty aggregation strategy.
News about Zymeworks often centers on clinical trial progress and key data readouts. A major theme is the development of Ziihera ® (zanidatamab-hrii), a HER2-targeted bispecific antibody engineered using the company’s Azymetric™ technology. Press releases have detailed positive Phase 3 HERIZON-GEA-01 results in first-line HER2-positive gastroesophageal adenocarcinoma, as well as regulatory approvals for previously treated HER2-positive biliary tract cancer in the U.S., Europe, and China. Updates also cover the advancement of partnered programs like pasritamig with Johnson & Johnson Innovative Medicine and early-stage data from wholly owned ADC candidates such as ZW191 and ZW251.
Investors following ZYME news can also expect regular coverage of strategic and corporate developments. The company reports on its evolving royalty- and asset-focused strategy, share repurchase authorizations, milestone and royalty revenues from partners, and leadership and board appointments designed to support capital allocation and partnership execution. Participation in major medical and investor conferences, such as ASCO GI and the J.P. Morgan Healthcare Conference, is another recurring topic in its news releases.
This news feed provides a centralized view of Zymeworks’ clinical milestones, partnership updates, financial and strategic announcements, and governance changes, offering context for how the company is executing its stated goal of building a diversified portfolio of revenue-generating healthcare assets alongside an active R&D engine.
Zymeworks (NASDAQ: ZYME) entered a $250 million non-recourse, royalty-backed note financing with Royalty Pharma on March 2, 2026. Repayments come from 30% of worldwide tiered royalties on Ziihera until repaid; Zymeworks retains 70% of royalties during repayment.
Royalty Pharma stops receiving payments after cumulative receipts of 1.65x the note by December 31, 2033 or 1.925x thereafter. Proceeds are non-dilutive, support share repurchases, potential strategic acquisitions, and extend cash runway beyond 2028. Zymeworks keeps up to $1.5 billion in remaining milestone payments tied to Ziihera.
Zymeworks (Nasdaq: ZYME) reported 2025 revenue of $106.0M (up 39% YoY) and a reduced net loss of $81.1M (down 34% YoY). Cash and marketable securities were $270.6M at year-end. The company closed a $250M non‑recourse royalty‑backed note and used $62.5M for share repurchases to March 2, 2026. Ziihera received approvals in Canada and the UK for biliary tract cancer, Jazz plans a potential U.S. GEA launch in 2H 2026, and up to $440M in GEA milestones are eligible.
Zymeworks (Nasdaq: ZYME) will report fourth quarter and full year 2025 financial results pre-market on March 2, 2026. Management will host a conference call and webcast the same day at 8:30 am Eastern Time to discuss results and provide a corporate update.
Zymeworks (Nasdaq: ZYME) said its management team will participate in several investor conferences in Feb–Mar 2026, including virtual and in-person events. Key engagements include one-on-one meetings at Citi’s 2026 Virtual Oncology Leadership Summit on Feb 18–19, 2026 (virtual); a one-on-one and a fireside chat at the TD Cowen 46th Annual Health Care Conference on Mar 2, 2026 at 14:30–15:00 ET in Boston; a one-on-one and fireside chat at the Leerink Annual Global Healthcare Conference on Mar 9, 2026 at 15:00 ET in Miami; and participation in the Citizens Life Science Conference on Mar 11, 2026 at 10:10 ET in Miami.
Zymeworks (Nasdaq: ZYME) announced board and leadership changes effective January 12, 2026 and early 2026 to align with its updated corporate strategy. Brian Cherry was appointed to the Board, bringing private equity and M&A experience. Mark Hollywood is promoted to Executive Vice President and Chief Operating Officer with expanded responsibilities. Dr. Sabeen Mekan will become Senior Vice President and Chief Medical Officer on February 1, 2026; current CMO Dr. Jeff Smith will retire January 31, 2026 and serve as an adviser during transition. The company initiated a search for a permanent CFO after departures in Q1 2026; Kenneth Galbraith is Acting CFO.
Zymeworks (Nasdaq: ZYME) outlined strategic priorities for 2026, highlighting positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2+ gastroesophageal adenocarcinoma and a planned supplemental BLA submission in 1H-2026. Key financials: potential regulatory milestones of $440.0M (US $250M, EU $100M, Japan $75M, China $15M), cash and marketable securities of approximately $270.6M as of Dec 31, 2025, and a $125.0M authorized share repurchase program (≈$19.0M used to date). Guidance includes ~$300.0M of adjusted gross operating expense (non-GAAP) over 2026–2028 and an expectation that cash plus anticipated milestones could fund operations beyond 2028.
Zymeworks (Nasdaq: ZYME) reported positive Phase 3 HERIZON-GEA-01 results: Ziihera (zanidatamab-hrii) plus chemotherapy, with or without tislelizumab, showed ~35% reduction in PFS risk versus trastuzumab plus chemotherapy and a median PFS of 12.4 months vs 8.1 months for control. The Ziihera+tislelizumab arm achieved a median OS of 26.4 months (a >7-month improvement; HR 0.72, P=0.0043), the longest reported in a Phase 3 GEA trial. Safety was consistent with HER2 and immunotherapy effects; higher Grade ≥3 TRAE rates were observed on the triple arm. Results will be presented at ASCO GI on Jan 8, 2026. Zymeworks is eligible for up to $440.0 million in GEA regulatory milestones.
Zymeworks (NASDAQ: ZYME) announced participation in upcoming investor and medical conferences in January 2026, including the ASCO Gastrointestinal Cancers Symposium (Jan 8–10, 2026) in San Francisco and the J.P. Morgan Annual Healthcare Conference (Jan 12–16, 2026).
At ASCO GI, Zymeworks will present a Trials-in-Progress poster for ZW251, a GPC3-targeting antibody-drug conjugate for hepatocellular carcinoma (Abstract TPS608) on Jan 9, 11:30 am–1:00 pm PT. A partner presentation will feature late-breaking data for HERIZON-GEA-01 (zanidatamab combinations) on Jan 8 (LBA285).
Management will hold a corporate presentation and one-on-one meetings at J.P. Morgan, with the corporate presentation scheduled for Jan 14, 2026 at 3:00 pm PT. Abstract release timings are Jan 5 at 2:00 pm PT (most abstracts) and late-breaking abstracts at presentation day 7:00 am PT.
Zymeworks (Nasdaq: ZYME) announced management will attend two investor conferences in Miami in early December 2025.
Management will take part in one-on-one meetings and a fireside chat at the Evercore 8th Annual Healthcare Conference on Dec 2, 2025 at 10:00 AM ET, and at the Citi 2025 Global Healthcare Conference on Dec 3, 2025 at 3:15 PM ET.
Zymeworks (Nasdaq: ZYME) appointed Scott Platshon as Acting Chief Investment Officer effective Nov 18, 2025. Platshon will report to CEO Kenneth Galbraith and manage expected future cash flows from Ziihera (zanidatamab-hrii) and other licensed assets, and lead the operational execution of the company’s healthcare asset aggregation strategy.
Platshon stepped down from Zymeworks' board and will serve part-time while continuing as a Partner at EcoR1 Capital. The role focuses on converting royalty and asset cash flows into a diversified, revenue-generating portfolio to support long-term shareholder returns.